AstraZeneca Results Presentation Deck
capivasertib
CAPItello-290
(1L mTNBC)
Extend beyond
PIK3/AKT/PTEN alterations
in unselected population
Robust Phase III catalysts in H2 2023
Key trial readouts reinforce transformative pipeline potential
Imfinzi
PACIFIC-2
(Stg. III unresec. NSCLC)
Potential to move 10
upfront + CCRT
Fasenra
MANDARA
(EGPA)
CEO Opening Remarks
Reinforcing first-choice
biologic in eosinophil
driven diseases
Imfinzi
EMERALD-1
(loco-regional HCC)
Financial Results
Potential to improve PFS vs
TACE therapy
Dato-DXd
TROPION-Breast01
(2L+ HR+/HER2- mBC)
Oncology
Building on TNBC efficacy,
expanding into HR+/HER2-
mBC (c.70% mBC subtypes)
AZD3152
SUPERNOVA
immuno-bridging sub-study
(COVID-19 prevention)
Next-gen prophylactic LAAB
for immunocompromised
(c.2% population)
BioPharmaceuticals
KI
XX
Rare Disease
CEO Closing Remarks
Total Revenue ambition¹:
low double-digit % 2021-2025
Industry-leading growth 2025+
Remain focused on Operating
Margin expansion
At least 15 NMES
approved by 2030
Emissions reduction:
98% by end 2025 - Scope 1 & 2
50% by 2030 - Scope 3
Confident in leading growth profile: base business strength with innovative late-stage pipeline
1. Indicates Company ambition to achieve Total Revenue low double-digit CAGR through 2025 (2021 base year, Alexion pro-forma) and industry-leading Total Revenue beyond 2025; this is not formal guidance. 1L = 1st-line; mTNBC = metastatic triple
negative breast cancer; PIK3/AKT/PTEN = phosphatidylinositol-3 kinase/protein kinase B/phosphatase and tensin homolog; EGPA = eosinophilic granulomatosis with polyangiitis; 2L+ = 2nd-line plus; HR+ = hormone receptor positive; HER2- = human
30 epidermal growth factor receptor 2 negative; mBC = metastatic breast cancer; Stg. = stage; unrecec. = unresectable; NSCLC = non-small cell lung cancer; CCRT = concurrent chemoradiation therapy; HCC = hepatocellular carcinoma; PFS = progression-
free survival; TACE = trans arterial chemoembolisation; LAAB = long-acting antibody; NME = new molecular entity.View entire presentation